Enabling better treatment of Multiple Myeloma
Thrasos is an early stage therapeutics company focused on the discovery, development and commercialization of innovative new drugs for rare disease indications within the kidney space. The company’s lead program is at the preclinical stage and is focused on myeloma cast nephropathy, a condition that effects up to 50% of patients with multiple myeloma. The company intends to file an IND by the end of 2017
Myeloma cast nephropathy is due to the obstruction of renal tubules by protein aggregates. It exposes patients to the risk of permanent kidney damage (including chronic dialysis), is associated with a decrease in survival and can impact the treatment of the underlying myeloma. There is no specific treatment for myeloma cast nephropathy and it represents and important unmet need.